secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2026-07-30T20:01:15+00:00
Accession:  0001193125-26-326083
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B
--------------------------------------------------------------------------------

- Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.
- Adjusted EBITDA $8.0M vs -$5.6M; FY2026 revenue guidance raised to $1.595-1.605B.
- Signed ~$200M in new Data and Applications licenses; MRD volume 9,000 tests.
- Agreed to acquire Personalis for $16.25/share (~$1.5B enterprise value).
- FDA approved xT Tumor Only CDx assay; first lab with both tumor-only and tumor-normal CDx.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000119312526326083/0001193125-26-326083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000119312526326083/tem-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-326083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer